CytoHub — Crafting Cells for Cures

Platform architecture

The three-vertex architecture.

Data generation → AI monetization → venture-scale optionality.

01Data engine

CardioVive™

Proprietary cardiac biology. Ground truth no competitor can source.

02AI monetization

CytoHub.AI™

Analytics licenses selling today. 80% gross margin.

03Cell therapy

HeartReady™

Allogeneic cell therapy for ischemic heart disease.

HeartReady

HeartReady™ — a living cellular therapy, delivered into post-MI scar.

We grow mature, manufacturable human cardiomyocytes designed to engraft and restore function in post‑MI scar. Clinical translation and manufacturing readiness are core to the program.

In Development UnderCardia Therapeutics

The problem

The heart never heals itself.

Dead muscle becomes scar — stiff, silent, permanent. The unmet need: post-MI scar & ischemic heart failure.

805K

Americans suffer a heart attack each year.

~90%

survive it. Modern cardiology is winning the first battle.

605K

Americans suffer their first MI each year.

50%

dead within five years — not waiting for another drug, but for new muscle.

The moat

The process is the product.

One iPSC becomes a mature ventricular cardiomyocyte: strong cardiac markers, adult-grade electrophysiology, oxidative metabolism. Anyone can grow a cell. The defensible asset is the route — the media, the timing, and the manufacturing — that does it reproducibly, at scale.

01

Proprietary differentiation

The signaling cocktail — growth factors, small molecules, timing — that drives a stem cell into a beating ventricular cardiomyocyte.

Methods · Media

02

Maturation protocol: EMM 2/1

The follow-up step that takes immature cells to adult-grade electrophysiology — the safety unlock for the field.

The safety unlock

03

Method of manufacturing

3D suspension bioreactor process with minimal batch-to-batch variability, end-to-end process analytics, and advanced cryopreservation.

3L → 15L scale

Patented 8 patent filings · methods · media · process · AI/ML

CytoHub.AI™

The operating system for biological intelligence.

The platform turns CardioVive data into actionable insight. CytoHub.AI ingests imaging, motion, sequencing, electrophysiology and bioprocess telemetry into a unified, queryable model.

01 · Inputs

Live-cell imaging
Motion / contractility
scRNA-seq
MEA / electrophysiology
Bioprocess telemetry

→

02 · Core

CytoHub.AI™

A unified embedding space across modalities, donors, and time. NVIDIA Inception · AWS.

→

03 · Application heads

CytoVision™ · imaging
CytoMotion™ · contractility
CytoRNA™ · scRNA-seq
CytoGPT™ · semantic

→

04 · Twin

CytoTWIN™

Patient-specific digital twins — simulate response before the first dose. A future premium module built on the same biological data stack.

Tissue alone is not the moat. The edge is the AI layer that turns biology into structured, queryable data — and the twin layer that lets partners simulate clinical response before dosing.

The wedge · flagship

CardioVive™: a beating heart model.

Our first commercial tissue wedge: iPSC-derived cardiac assembloids with functional chambers, electrical activity, and resident immune cells — predictive of human pharmacology where animal models fail. CardioVive is the data engine that powers CytoHub.AI analytics.

96%

Native cardiac cell composition

60d+

Functional in culture

3

Drug classes validated

Validated against

Dofetilide · hERG Ondansetron · 5-HT3 Paroxetine · SSRI

CardioVive beating heart model demo showing motion vectors and velocity mapping — Live CardioVive motion-vector and beating-velocity readout

Scientifically de-risked

The science already works — and ours is peer-reviewed.

The cell-therapy field is independently validated by the world's leading cardiac labs. Our own platform doesn't rest on a pitch — it rests on peer-reviewed publications underpinning every layer of the stack.

The field · independent validation

2014

Stem-cell cardiomyocytes regenerate primate hearts

~40% of the infarct remuscularized with electromechanical coupling.

Chong, Murry et al. · Nature

2018

hESC-CMs restore function in infarcted primates

Intramyocardial delivery → +10–12 point gain in LVEF at 12 weeks.

Liu et al. · Nature Biotechnology

2024

Mature iPSC-cardiac spheroids regenerate primate hearts

Purified, matured cells → durable engraftment; transient arrhythmia resolved by week 2.

Kobayashi, Tohyama et al. · Circulation

2025

First-in-human, 48-month follow-up

n=2, alive at 4 years · LVEF improved · NYHA IV→II · no tumors.

Zhang et al. · JACC: Basic to Translational Science

Our science · the platform, published

2021

Self-assembling human heart organoids Nature Communications

The foundational protocol — organoids with atrial, ventricular & proepicardial regions that benchmark to 6–13-week human hearts.

Lewis-Israeli et al. · Aguirre Lab

2023

Patterned primitive heart organoid & EMM2/1 maturation Nature Communications

Defined cell-type ratios and adult-grade electrophysiology — the maturation step that is the safety unlock for the field.

Volmert et al. · Aguirre Lab

2024

Neural-crest heart assembloids preprint · under review

Modeling fetal cardiac development and SSRI cardiotoxicity in a neural-crest-integrated assembloid.

Kostina et al. · bioRxiv

Neural crest heart assembloid visualization — NeuralCrest model visualization

2025

Tissue-resident macrophage integration Cell Stem Cell

CardioPhage™ biology — TRMPs integrate via Cx43 gap junctions, persist 60+ days, and improve cardiac maturation.

O'Hern et al.

Traction

Real revenue. Real partners. Already backed.

$8.4M+

Non-dilutive funding to MSU for underlying biology R&D

Worldwide

Exclusive MSU platform license · executed 2026

8

Patent families · 4 tissue + 4 AI/data

4 delivered

Commercial partners · 1 acquired

Delivered 4 commercial partners (1 acquired)

In pilot 3 commercial partners, including a pharma partner

In discussion 6 big pharma partners, 4 CROs

Commercial demand is outpacing our current capacity.

The people

Built cell therapies before. Doing it again with AI/ML and Smart Manufacturing.

A compact executive team engineers biology, analytics, and process, while advisors and consultants accelerate commercial launch, manufacturing, and translational validation.

Leadership

Rajib Biswas, PhD

CEO & Co-founder

Led cardiac cell therapy at Sana and technical evaluation at Resilience; UW Heart Regeneration Program and Stanford GSB.

Aitor Aguirre, PhD

Head of R&D · Co-founder

Inventor of MSU's human heart-organoid platform; NHLBI highlighted his synthetic heart development work as a major cardiac-research advance.

Frank Teoh, MS

VP Engineering · Co-founder

20+ years in ML and large-scale data at Yahoo, Chime, and Oracle; nine patents; Cornell M.Eng and Stanford GSB executive program.

Richard J. Anderson, PhD

VP Technical Operations

Employee #5 at Oxxon (concept to IND and exit); Pfizer and NantKwest veteran who built MSAT at Fate Therapeutics.

Anand Giddabasappa, PhD

Advisor, Translational Pharmacology

15+ years in translational pharmacology and preclinical modeling, advising efficacy and predictive safety strategy.

Advisors

Rahul Singhvi, ScD

Advisor, commercialization strategy

Former CEO of Resilience and Novavax, advising go-to-market strategy, multibillion-dollar business building, and investor network expansion.

Randy Berholtz, JD

Strategic Advisor

Life science entrepreneur, venture capitalist, and lawyer who has spent over 25 years as a CEO to two private biotech companies.

Chris Nowers

Advisor, strategic partnerships

Former ONK CEO and Kite Europe head advising commercialization, partnerships, and international growth.

Mohammad El-Kalay, PhD

Advisor, CMC & scalable manufacturing

Expert in cell-therapy process development, quality systems, and GMP-ready manufacturing for clinical programs.

Anand Giddabasappa, PhD

Advisor, Translational Pharmacology

15+ years in translational pharmacology and preclinical modeling, advising efficacy and predictive safety strategy.

Vish Krishnan, PhD

Advisor, Jacobs Family Chair in Management and Engineering Leadership

Faculty Director at Rady and CIID, advising innovation, entrepreneurship, product management, and startup growth.

R&D & Engineering

Matthieu Bauer, PhD

Assoc. Director, Process Dev

13 years in hESC/hiPSC biology and cardiomyocyte differentiation; scientific lead for CardioVive and HeartReady.

Nagasoujanya Annasamudram, PhD

Team Lead, CytoHub.AI

ML engineer focused on biomedical imaging and single-cell sequencing workflows; PhD in Applied Mathematics.

Satish Kumar, PhD

AI/ML Lead Engineer

Leads applied AI/ML engineering, turning complex models into dependable production systems.

Madhoolika C

CytoHub.AI Intern

Supports CytoHub.AI workflows across data analysis, model development, and AI-enabled biological insights.

Hriddhy Hazra

CytoHub.AI Intern

Supports CytoHub.AI workflows across data analysis, model development, and AI-enabled biological insights.

Rista White

Research Associate I

Recent UCLA grad passionate about neuroscience and stem cell biology research, illustration, and science communication.

Consultants

Brynley Lee

Executive Consultant, Corp. Dev. & Commercialization

Six-time CEO who has raised millions in capital and engineered exits from both sides of the negotiating table — buyer and seller alike — most recently at the helm of Basilard BioTech.

Matthew J. Pelo

Consultant, Finance (Fractional CFO)

Fractional CFO supporting financial strategy, planning, and operations.

Oscar Abilez, MD, PhD

Principal Consultant

Stanford-trained cardiovascular tissue engineer advising translational bioengineering and tissue fidelity.

Najah Abi-Gerges, PhD

Principal Consultant

22+ years in cardiac drug discovery across translational research and preclinical development.

Erez Perry, PhD

Senior Consultant, Cell-based Assay

Specialist in cell-based assay development and translational biology, supporting validation and assay strategy.

Sammantha Caywood

Consultant

Supports lab operations with hands-on cell and tissue culture work across CytoHub programs.

Backed by · Johnson & Johnson JLABS · CytoHub.AI™ · NVIDIA Inception · AWS · NIH · AHA · NSF · MSU Research Foundation · Red Cedar Ventures

Regenerating the heart with living muscle.

The three-vertex architecture.

CardioVive™

CytoHub.AI™

HeartReady™

HeartReady™ — a living cellular therapy, delivered into post-MI scar.

The heart never heals itself.

The process is the product.

Proprietary differentiation

Maturation protocol: EMM 2/1

Method of manufacturing

The operating system for biological intelligence.

CardioVive™: a beating heart model.

The science already works — and ours is peer-reviewed.

Stem-cell cardiomyocytes regenerate primate hearts

hESC-CMs restore function in infarcted primates

Mature iPSC-cardiac spheroids regenerate primate hearts

First-in-human, 48-month follow-up

Self-assembling human heart organoids Nature Communications

Patterned primitive heart organoid & EMM2/1 maturation Nature Communications

Neural-crest heart assembloids preprint · under review

Tissue-resident macrophage integration Cell Stem Cell

Real revenue. Real partners. Already backed.

Built cell therapies before. Doing it again with AI/ML and Smart Manufacturing.

Together, we can re-build the heart after heart attack.